{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:45Z","timestamp":1789689645422,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.hlc.2012.12.002","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T19:46:43Z","timestamp":1358538403000},"page":"323-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Therapeutic Potential of Tumour Necrosis Factor-alpha Antagonists in Patients with Chronic Heart Failure"],"prefix":"10.1016","volume":"22","author":[{"given":"Qamar","family":"Javed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iram","family":"Murtaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hlc.2012.12.002_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0021-9150(02)00429-X","article-title":"A polymorphism in the promoter of the tumor necrosis factor-alpha gene (\u2212308) is associated with coronary heart disease in type 2 diabetic patients","volume":"167","author":"Vendrell","year":"2003","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.hlc.2012.12.002_bib0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.GIM.0000170993.75385.F4","article-title":"Association between TNF-alpha \u2212308G>A polymorphism and the development of acute coronary syndromes in Greek subjects: the CARDIO2000-GENE Study","volume":"7","author":"Dedoussis","year":"2005","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.hlc.2012.12.002_bib0015","first-page":"1991","article-title":"In situ expression of cytokines in human heart allografts","volume":"149","author":"Van Hoffen","year":"1996","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.hlc.2012.12.002_bib0020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0022-5223(96)70068-5","article-title":"Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass","volume":"112","author":"Wan","year":"1996","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1016\/j.hlc.2012.12.002_bib0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0167-5273(99)00144-8","article-title":"Elevated tumor necrosis factor alpha of blood mononuclear cells in patients with congestive heart failure","volume":"71","author":"Zhao","year":"1999","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.hlc.2012.12.002_bib0030","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2165\/00003495-200060060-00002","article-title":"Tumors necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications","volume":"60","author":"Bolger","year":"2000","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.hlc.2012.12.002_bib0035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hlc.2012.12.002_bib0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1568010023344535","article-title":"TNF alpha as therapeutic target: new drugs, more applications","volume":"1","author":"Reimold","year":"2002","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"25","key":"10.1016\/j.hlc.2012.12.002_bib0045","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","article-title":"Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure","volume":"99","author":"Deswal","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hlc.2012.12.002_bib0050","first-page":"27","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"24","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hlc.2012.12.002_bib0055","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1172\/JCI118090","article-title":"Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration","volume":"96","author":"Kapadia","year":"1995","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1016\/j.hlc.2012.12.002_bib0060","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/01.CIR.97.14.1382","article-title":"Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats","volume":"97","author":"Bozkurt","year":"1998","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.hlc.2012.12.002_bib0065","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1161\/01.CIR.101.21.2518","article-title":"Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy","volume":"101","author":"Kubota","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hlc.2012.12.002_bib0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/exmp.2002.2450","article-title":"Tumor necrosis factor-alpha eluting stents reduce vascular smooth muscle cell proliferation in saphenous vein organ culture","volume":"73","author":"Javed","year":"2002","journal-title":"Exp Mol Pathol"},{"issue":"5","key":"10.1016\/j.hlc.2012.12.002_bib0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med"},{"issue":"7\u20138","key":"10.1016\/j.hlc.2012.12.002_bib0080","first-page":"289","article-title":"Echocardiographic evaluation of anti-tumor necrosis factor-alpha therapy with infliximab in patients without cardiac pathologies","volume":"101","author":"Bargangi","year":"2010","journal-title":"Recenti Prog Med"},{"issue":"2\u20133","key":"10.1016\/j.hlc.2012.12.002_bib0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-5273(02)00470-9","article-title":"How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH","volume":"86","author":"Anker","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2012.12.002_bib0090","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.hlc.2012.12.002_bib0095","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hlc.2012.12.002_bib0100","first-page":"233","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"17","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hlc.2012.12.002_bib0105","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hc3501.096063","article-title":"Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model","volume":"104","author":"Kadokami","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hlc.2012.12.002_bib0110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.hlc.2012.12.002_bib0115","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.hlc.2012.12.002_bib0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1507\/endocrj.K07E-043","article-title":"Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody","volume":"55","author":"Nishida","year":"2008","journal-title":"Endocrine Journal"},{"issue":"April (3)","key":"10.1016\/j.hlc.2012.12.002_bib0125","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.hlc.2012.12.002_bib0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2007.08.013","article-title":"TNF-\u03b1 blockade in human diseases: mechanisms and future directions","volume":"126","author":"Wong","year":"2008","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.hlc.2012.12.002_bib0135","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/art.11168","article-title":"Polymorphism at position \u2212308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis","volume":"48","author":"Mugnier","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.hlc.2012.12.002_bib0140","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2036.2005.02635.x","article-title":"Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease","volume":"22","author":"Hlavaty","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hlc.2012.12.002_bib0145","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1253\/circj.72.850","article-title":"Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm","volume":"72","author":"Oishi","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.hlc.2012.12.002_bib0150","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1203\/00006450-200105000-00013","article-title":"Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease","volume":"49","author":"Quasney","year":"2001","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.hlc.2012.12.002_bib0155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2036.2004.01946.x","article-title":"Tumors necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab","volume":"20","author":"Pierik","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hlc.2012.12.002_bib0160","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.7914033","article-title":"A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells","volume":"265","author":"Han","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.hlc.2012.12.002_bib0165","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0167-4889(95)00002-A","article-title":"Molecular cloning of the p38 MAP kinase","volume":"16","author":"Han","year":"1995","journal-title":"Biochim Biophys Acta"},{"issue":"6508","key":"10.1016\/j.hlc.2012.12.002_bib0170","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/372739a0","article-title":"A protein kinase involved in the regulation of inflammatory cytokine biosynthesis","volume":"372","author":"John","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.hlc.2012.12.002_bib0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/jlb.59.2.152","article-title":"Role of CSB\/p38\/RK stress response kinase in LPS and cytokine signalling mechanisms","volume":"59","author":"Lee","year":"1996","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.hlc.2012.12.002_bib0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-2249.2001.01485.x","article-title":"Supression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers","volume":"124","author":"Fijen","year":"2001","journal-title":"Clin Exp Immunol"},{"issue":"19","key":"10.1016\/j.hlc.2012.12.002_bib0185","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1021\/jm050165o","article-title":"Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl] benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent","volume":"48","author":"Miwatashi","year":"2005","journal-title":"J Med Chem"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950612013972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950612013972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:58:41Z","timestamp":1761415121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950612013972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1443950612013972"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2012.12.002","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Potential of Tumour Necrosis Factor-alpha Antagonists in Patients with Chronic Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2012.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}